IMMUNITYBIO, INC. (IBRX)
ImmunityBio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7x Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash and Marketable Securities Total $381 Million
📈 **POSITIVE** • High confidence analysis (83%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business